MA50541A - Formulations pharmaceutiques - Google Patents

Formulations pharmaceutiques

Info

Publication number
MA50541A
MA50541A MA050541A MA50541A MA50541A MA 50541 A MA50541 A MA 50541A MA 050541 A MA050541 A MA 050541A MA 50541 A MA50541 A MA 50541A MA 50541 A MA50541 A MA 50541A
Authority
MA
Morocco
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
MA050541A
Other languages
English (en)
Inventor
Joanna M Koziara
Scott Mccallister
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56418608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50541(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MA50541A publication Critical patent/MA50541A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA050541A 2015-06-30 2016-06-29 Formulations pharmaceutiques MA50541A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562187113P 2015-06-30 2015-06-30
US201662298373P 2016-02-22 2016-02-22
US201662301429P 2016-02-29 2016-02-29
US201662317286P 2016-04-01 2016-04-01

Publications (1)

Publication Number Publication Date
MA50541A true MA50541A (fr) 2021-04-07

Family

ID=56418608

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050541A MA50541A (fr) 2015-06-30 2016-06-29 Formulations pharmaceutiques

Country Status (26)

Country Link
US (2) US20180177734A1 (fr)
EP (5) EP4070788B1 (fr)
JP (3) JP6667556B2 (fr)
KR (2) KR102121329B1 (fr)
CN (1) CN107847450A (fr)
AU (3) AU2016287500B2 (fr)
BR (1) BR112017027843A2 (fr)
CA (1) CA2990210C (fr)
CL (1) CL2017003320A1 (fr)
CO (1) CO2017013293A2 (fr)
CU (1) CU20170168A7 (fr)
DO (1) DOP2017000306A (fr)
EA (1) EA201792592A1 (fr)
EC (1) ECSP17084331A (fr)
ES (4) ES2945345T3 (fr)
HK (1) HK1248547A1 (fr)
IL (1) IL256364A (fr)
MA (1) MA50541A (fr)
MX (1) MX2017016806A (fr)
PE (1) PE20180411A1 (fr)
PH (1) PH12017502431A1 (fr)
PL (4) PL4070787T3 (fr)
PT (4) PT3607939T (fr)
SI (4) SI4070787T1 (fr)
SV (1) SV2017005601A (fr)
WO (1) WO2017004244A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2926068T3 (es) 2012-12-21 2022-10-21 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
RS62434B1 (sr) 2014-12-26 2021-11-30 Univ Emory Antivirusni n4-hidroksicitidin derivati
SG11201802983TA (en) 2015-11-09 2018-05-30 Gilead Sciences Inc Therapeutic compositions for treatment of human immunodeficiency virus
MX2021015220A (es) 2017-02-17 2022-12-01 Eidos Therapeutics Inc Procesos para preparar ácido 3-(3-(3,5-dimetil-1h-pirazol-4-il)pro poxi)-4- 5-fluorobenzoico (ag-10), sus compuestos intermedios, y sales del mismo.
WO2018153977A1 (fr) * 2017-02-24 2018-08-30 Hexal Ag Composition stable de ténofovir alafénamide
US11191763B2 (en) 2017-03-20 2021-12-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HIV post-exposure prophylaxis
RU2662160C9 (ru) 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
CN111372592A (zh) 2017-12-07 2020-07-03 埃默里大学 N4-羟基胞苷及衍生物和与其相关的抗病毒用途
SG11202009073WA (en) 2018-03-23 2020-10-29 Eidos Therapeutics Inc Methods of treating ttr amyloidosis using ag10
EP3836920A4 (fr) 2018-08-17 2022-04-13 Eidos Therapeutics, Inc. Formules d'ag10
CN111096954B (zh) * 2018-10-29 2022-09-16 江苏豪森药业集团有限公司 一种用于抗病毒感染的药物组合物及制备方法
CN110251476B (zh) * 2019-08-01 2022-08-09 海思科制药(眉山)有限公司 一种恩曲他滨替诺福韦药物组合物
CN110917197A (zh) * 2019-12-31 2020-03-27 常州恒邦药业有限公司 一种替诺福韦酯与恩曲他滨的药物组合物及其制备方法
TWI728709B (zh) * 2020-02-19 2021-05-21 台灣森本生物科技開發股份有限公司 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方
CN117338733B (zh) * 2023-10-12 2024-05-28 杭州和泽坤元药业有限公司 一种富马酸替诺福韦二吡呋酯片及其制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001282941C1 (en) 2000-07-21 2016-12-22 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
ATE398455T1 (de) * 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
SG10201706215UA (en) 2009-02-06 2017-08-30 Gilead Sciences Inc Tablets for combination therapy
US8754065B2 (en) 2011-08-16 2014-06-17 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
KR20140119177A (ko) * 2012-02-03 2014-10-08 길리애드 사이언시즈, 인코포레이티드 바이러스 감염의 치료에 사용하기 위한 테노포비르 알라페나미드 헤미푸마레이트 및 코비시스타트를 포함하는 조합 요법
JP2016528240A (ja) * 2013-08-14 2016-09-15 ラシオファルム ゲーエムベーハー ドルテグラビル、エムトリシタビン及びテノホビルの医薬コンビネーションを有する医薬
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
NO2717902T3 (fr) * 2014-06-20 2018-06-23

Also Published As

Publication number Publication date
AU2016287500A1 (en) 2018-01-18
BR112017027843A2 (pt) 2018-09-04
EP4070788A1 (fr) 2022-10-12
CN107847450A (zh) 2018-03-27
IL256364A (en) 2018-02-28
ES2945345T3 (es) 2023-06-30
CU20170168A7 (es) 2018-07-05
ES2925246T3 (es) 2022-10-14
ECSP17084331A (es) 2018-01-31
PL3316868T3 (pl) 2020-10-19
JP6667556B2 (ja) 2020-03-18
EP4070788B1 (fr) 2023-03-22
EP4233846A2 (fr) 2023-08-30
PL3607939T3 (pl) 2022-11-07
JP6978534B2 (ja) 2021-12-08
JP2021185188A (ja) 2021-12-09
CO2017013293A2 (es) 2018-05-31
AU2021202009A1 (en) 2021-04-29
AU2019210558B2 (en) 2021-04-22
PT4070788T (pt) 2023-06-06
JP2018519297A (ja) 2018-07-19
KR102121329B1 (ko) 2020-06-17
AU2019210558A1 (en) 2019-08-15
PT3316868T (pt) 2020-04-21
EP4233846A3 (fr) 2023-10-04
AU2016287500B2 (en) 2019-05-02
SI3607939T1 (sl) 2022-10-28
EP3607939A1 (fr) 2020-02-12
PL4070787T3 (pl) 2023-07-24
SV2017005601A (es) 2018-05-04
HK1248547A1 (zh) 2018-10-19
KR20180021134A (ko) 2018-02-28
PE20180411A1 (es) 2018-03-01
PL4070788T3 (pl) 2023-07-10
EP3316868B1 (fr) 2020-02-19
US20170000807A1 (en) 2017-01-05
KR102313668B1 (ko) 2021-10-19
ES2786549T3 (es) 2020-10-13
CA2990210A1 (fr) 2017-01-05
JP2020079304A (ja) 2020-05-28
AU2021202009B2 (en) 2023-04-13
MX2017016806A (es) 2018-05-07
EP3316868A1 (fr) 2018-05-09
PT4070787T (pt) 2023-05-22
ES2945896T3 (es) 2023-07-10
PT3607939T (pt) 2022-09-12
EA201792592A1 (ru) 2018-06-29
EP4070787A1 (fr) 2022-10-12
EP3607939B1 (fr) 2022-06-01
SI4070787T1 (sl) 2023-07-31
PH12017502431A1 (en) 2018-07-02
KR20200067937A (ko) 2020-06-12
CL2017003320A1 (es) 2018-07-13
US20180177734A1 (en) 2018-06-28
WO2017004244A1 (fr) 2017-01-05
EP4070787B1 (fr) 2023-03-01
DOP2017000306A (es) 2018-01-15
SI3316868T1 (sl) 2020-04-30
CA2990210C (fr) 2021-01-12
SI4070788T1 (sl) 2023-06-30

Similar Documents

Publication Publication Date Title
MA50541A (fr) Formulations pharmaceutiques
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
MA42303A (fr) Formulations pharmaceutiques
MA46867A (fr) Formulations pharmaceutiques
DK3634377T3 (da) Farmaceutisk formulering
MA54716A (fr) Réduction de la viscosité de formulations pharmaceutiques
MA45187A (fr) Combinaisons pharmaceutiques
DK3199161T3 (da) Farmaceutisk præparat
MA44987A (fr) Formulations de médicaments améliorées
MA49837A (fr) Compositions pharmaceutiques
DK3583943T3 (da) Farmaceutisk sammensætning
DK3191085T3 (da) Misbrugsresistente farmaceutiske sammensætninger
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
ZA201707094B (en) Pharmaceutical formulations
ES2981002T3 (es) Formulación farmacéutica
DK3601277T3 (da) Farmaceutisk formulering
DK3256138T3 (da) Farmaceutiske sammensætninger omfattende meloxicam
DK3288967T3 (da) Farmaceutisk forbindelse
TR201503831A2 (tr) Antimipertansif kombinasyon formülasyonları
DK3089740T3 (da) Farmaceutisk sammensætning
MA49625A (fr) Compositions pharmaceutiques
DK3481370T3 (da) Farmaceutisk sammensætning omfattende benzydamin
DK3558261T3 (da) Farmaceutiske sammensætninger omfattende safinamid
MA42111A (fr) Compositions pharmaceutiques topiques